Want to see ALMS full AI Analyst Report?
ALMS Stock Chart & Stats
$28.00
-$0.30(-1.06%)
At close: 4:00 PM EDT
$28.00
-$0.30(-1.06%)
Day’s Range― - ―
52-Week Range$3.76 - $31.35
Previous CloseN/A
Volume1.16M
Average Volume (3M)1.58M
Market Cap
$3.23B
Enterprise Value$3.13K
Total Cash (Recent Filing)$502.29M
Total Debt (Recent Filing)$36.43M
Price to Earnings (P/E)―
Beta-1.29
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding123,432,076
10 Day Avg. Volume1,117,677
30 Day Avg. Volume1,579,261
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)27.54
Price to Sales (P/S)345.07
P/FCF Ratio-22.42
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$41.14Price Target Upside46.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Durable Phase 3 EfficacySustained high skin-clearance rates and a favorable safety profile strengthen envudeucitinib’s potential differentiation among oral psoriasis therapies and support a durable regulatory and commercial opportunity.
Broad TYK2 PipelineA shared TYK2 platform spanning multiple immune diseases could diversify future indications and improve the value of Alumis’s research infrastructure if clinical results continue to validate maximal target engagement.
Low Financial LeverageLow debt reliance reduces interest and refinancing pressure, giving Alumis greater flexibility to fund clinical development through its current programs while limiting the balance-sheet risks often associated with cash-burning biotech companies.
Bears Say
Severe Cash BurnDeeply negative operating and free cash flow means internal funds do not cover development needs, leaving Alumis dependent on future equity, debt, or partnership financing before product revenue can scale.
Large Operating LossesVery large losses relative to limited revenue show that the company has not yet achieved operating leverage. Continued high research and development spending could prolong losses even if clinical progress remains positive.
No Established Product RevenueWithout an approved commercial therapy, revenue remains uncertain and dependent on funding or strategic transactions. Delays, weak trial outcomes, or regulatory setbacks could therefore extend the pre-commercial period and financing risk.
Alumis Inc. News
ALMS FAQ
What was Alumis Inc.’s price range in the past 12 months?
Alumis Inc. lowest stock price was $3.76 and its highest was $31.35 in the past 12 months.
What is Alumis Inc.’s market cap?
Alumis Inc.’s market cap is $3.23B.
When is Alumis Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Alumis Inc.’s earnings last quarter?
Currently, no data Available
Is Alumis Inc. overvalued?
According to Wall Street analysts Alumis Inc.’s price is currently Undervalued.
Does Alumis Inc. pay dividends?
Alumis Inc. does not currently pay dividends.
What is Alumis Inc.’s EPS estimate?
Alumis Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Alumis Inc. have?
Alumis Inc. has 123,432,076 shares outstanding.
What happened to Alumis Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Alumis Inc.?
Currently, no hedge funds are holding shares in ALMS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alumis Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$41.14 (46.94% Upside)
$41.14 (46.94% Upside)
Blogger Sentiment
Neutral
ALMS Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 294.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $327.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.1%
Last 30 Days ▼ 5.4%
Last 30 Days ▼ 5.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
625.38%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-8.23%
Trailing 12-Months
Company Description
Alumis Inc.
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
ALMS Stock 12 Month Forecast
Average Price Target
$41.14
▲(46.94% Upside)
Technical Analysis
Ownership Overview
43.93% Insiders
9.45% Mutual Funds
15.00% Other Institutional Investors
22.07% Public Companies and
Individual Investors